Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Trial Details

NCT ID

NCT06190067

Phase

PHASE2

Sponsor

Navy General Hospital, Beijing

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Azacitidine Plus PD-1 therapy

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification.
• Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
• Patient is willing and able to adhere to the study visit schedule and other protocol requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.